News
Hosted on MSN5mon
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%Longboard Pharmaceuticals LBPH announced that ... as an adjunctive treatment in patients with FOS. Xenon expects to complete patient enrollment in the X-TOLE2 study in late 2024 to early 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback